Since August 2019, a Phase I clinical trial (NCT03976349) has begun to evaluate this 2‐MOE ASO (BIIB094) through intrathecal administration in PD patients with or without a PD‐related LRRK2 mutation. Here, LRRK2 is linked to Parkinson disease.